Overview

Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer

Status:
Completed
Trial end date:
2015-03-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of foretinib (also known as GSK1363089) when used in the treatment of patients with advanced hepatocellular carcinoma (liver cancer).
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline